Evaluating Baricitinib for treating Frontal Fibrosing Alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and effectiveness of Baricitinib, an oral medication, in treating frontal fibrosing alopecia (FFA) in post-menopausal women. Participants will be evaluated based on specific criteria, including the presence of active FFA and certain clinical features such as eyebrow loss and hairline recession. The study will involve administering Baricitinib and monitoring its impact on the condition over a defined period. The trial is designed to provide insights into the potential benefits of this treatment for affected individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female at least 18 years of age, and able to provide informed consent
* Females who are post-menopausal defined, as not have menses for at least 12 months without an alternative medical cause and elevated follicle stimulating hormone in the postmenopausal range as measured during screening
* Have active FFA that has been diagnosed on or prior to screening visit.
* Have LPPAI score equal to or greater than 5 at screening.
* Have evidence of eyebrow loss at baseline
* Have evidence of hairline recession at baseline
* Have classic presentation with frontal loss of scalp hair
* Negative screening for tuberculosis (Quantiferon Gold, T-spot) within 3 months prior to screening or at the screening visit.
* Agree not to have a live vaccination during the study the exception is herpes zoster vaccine

Exclusion Criteria:

* Systemic treatments for FFA within 4 weeks of the baseline visit or 5 half lives whichever one is longer. (ex: finasteride, pioglitazone, hydroxychloroquine, or immunosuppressant medications, such as mycophenolate mofetil).
* Dutasteride within the last 6 months
* Have a LPPAI score less than 5 at screening
* Immunocompromised and with risk factors concerning to investigator for study participation
* Previous treatment with an oral JAK inhibitor
* Any condition in the opinion of the investigator which would interfere with the study assessments or procedure
* Subject is pregnant or breast feeding
* Surgical intervention including face lifts and micro-blading on the treatment areas
* Any intervention (facelifts micro blading) that could affect the treatment areas (i.e. scalp and eyebrows)
* Laser or phototherapy intervention on the treatment areas
* Have evidence of active TB or latent TB

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting

Study contacts

• Principal investigator: Boni Elewski, MD — University of Alabama at Birmingham
• Study coordinator: Ralee' Bunt, MSPH
• Email: erikabunt@uabmc.edu
• Phone: 205-502-9960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Baricitinib for persistent low platelets after stem cell transplant

  We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07535645

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

• Telitacicept plus baricitinib for refractory rheumatoid arthritis

  This test tries combining telitacicept with baricitinib to see if it helps adults with refractory rheumatoid arthritis who haven't improved on other treatments.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07491016

• Face facial papules in frontal fibrosing alopecia: laser treatment using AviClear

  We are testing whether the Cutera 1726 nm laser can safely and effectively reduce facial papules in people with frontal fibrosing alopecia.

  Recruiting University of Miami · Miami, Florida · NCT07340671

• Baricitinib Added to Corticosteroids in PMR (Polymyalgia Rheumatica) May Improve Control

  This study tests whether baricitinib plus low-dose steroids works better than steroids alone for people 50 and older with PMR.

  Recruiting at 19 sites Phase 3 University Hospital, Brest · Aix-en-Provence and 22 other locations · NCT07279688

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.